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ABACKGROUND Arrhythmogenic right ventricular cardiomyopathy
(ARVC) is an inherited heart muscle disease carrying a risk of
sudden death. Information about the clinical features during
childhood and the age at disease onset is scanty.
OBJECTIVE The aim of the study was to describe the ARVC phe-
notype as its initial clinical manifestation in a pediatric popula-
tion (18 years) with desmosomal gene mutations.
METHODS Fifty-three ARVC desmosomal gene mutation carriers
(mean age 12.3  3.9 years) were investigated by electrocardio-
gram (ECG), signal-averaged ECG, 24-hour Holter, echocardiogram,
and contrast-enhanced cardiac magnetic resonance (CMR).
RESULTS None of the children 10 years old fulfilled the 1994
riteria, as opposed to six (33%) aged 11–14 years and eight aged
14 years (42%). At the end of follow-up (9 7 years), 21 (40%)
ulfilled the 1994 diagnostic criteria (mean age 16  4 years). By
sing the 2010 criteria in subjects aged 18 years, 53% were
naffected, versus 62% by using the traditional criteria. More than
wo-thirds of affected subjects had moderate-severe forms of the
isease. Contrast-enhanced CMR was performed in 21 (40%); of 13
naffected gene mutation carriers, six showed ARVC morphologicali
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1547-5271/$ -see front matter © 2011 Heart Rhythm Society. All rights reservedONCLUSION In pediatric ARVC mutation carriers, a diagnosis
as achieved in 40% of cases, confirming that the disease usually
evelops during adolescence and young adulthood. The 2010 mod-
fied criteria seem to be more sensitive than the 1994 ones in
dentifying familial pediatric cases. Contrast-enhanced CMR can
rovide diagnostic information on gene mutation carriers not
ulfilling either traditional or modified criteria. Management of
symptomatic gene mutation carriers remains the main clinical
hallenge.
BBREVIATIONS ARVC  arrhythmogenic right ventricular car-
diomyopathy; BSA  body surface area; CMR  cardiac magnetic
resonance; ECG  electrocardiogram; LE  late enhancement;
LV  left ventricular, ventricle; LVEF  left ventricular ejection
fraction; LVEDV  left ventricular end diastolic volume; MM 
multiple mutations; PLAX  parasternal long axis; PSAX  para-
sternal short axis; PVC  premature ventricular complex; RV 
right ventricular; RVEDA  right ventricular end-diastolic area;
RVEDV  right ventricular end-diastolic volume; RVFS  right
ventricular fraction shortening; RVOT  right ventricular outflow
tract; SAECG  signal-averaged electrocardiogram; VF  ventric-
ular fibrillation; VT  ventricular tachycardia
(Heart Rhythm 2011;8:1686–1695) © 2011 Heart Rhythm Society.
nd/or tissue abnormalities. All rights reserved.Introduction
Major advances have been made in our understanding of
arrhythmogenic right ventricular cardiomyopathy (ARVC)
in the last few years, primarily involving the detection of
This study was supported by TELETHON, Rome GGP09293; Fonda-
zione CARIPARO, Padua, Italy; and Registry of Cardio-Cerebro-Vascular
Pathology, Veneto Region, Venice, Italy. Address for reprints and cor-
respondence: Barbara Bauce, M.D., Ph.D., Department of Cardiac Tho-
acic and Vascular Sciences, Via Giustiniani, 2 35128, Padua, Italy. E-mail
ddress: barbara.bauce@unipd.it. (Received November 17, 2010; acceptedseveral disease-causing genes that encode mainly for des-
mosomal proteins.1–9 Genotype-phenotype correlation stud-
es have demonstrated that subjects carrying mutations of
he same gene may have different clinical features and
isease extent, in terms of right (RV) and left (LV) ventric-
lar dimensional and kinetics as well as of electrical insta-
ility.10–15 Most available data on the clinical picture of
RVC come from observations in adults, while there is
ittle information on the signs and symptoms of the disease
n childhood and adolescence16–18 and none on genotype-phenotype correlation in this age group.
. doi:10.1016/j.hrthm.2011.06.026
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1687Bauce et al Desmosomal Gene MutationsThe present study was designed to analyze a series of
ARVC-desmosomal gene mutation carriers first assessed at
a young age in an outpatient clinic as part of a family
screening program for inherited cardiomyopathies to eluci-
date the disease phenotype in terms of clinical onset and
natural history.
Methods
Study population
Fifty-three subjects (31 males and 22 females) belonging to
27 families and evaluated at our center from 1980 to 2008
before the age of 18 and carrying desmosomal genes mu-
tations were analyzed. The study was partly retrospective
because genetic data were obtained for some cases when
they had already joined the yearly follow-up program after
family screening for ARVC. Based on their age at first
observation, patients were divided into three age groups:
group A10 years; group B 11–14 years; group C14–18
years.
Genetic study
Screening for mutations in the plakophilin-2 (PKP2), des-
moplakin (DSP), desmoglein-2 (DSG2), desmocollin-2
(DSC2), and plakoglobin (JUP) genes was done by dena-
turing high-performance liquid chromatography and direct
sequencing. The analysis was conducted using the WAVE
Nucleic Acid Fragment Analysis System 3500HT with
DNASep HT cartridge technology (Transgenomic Ltd NE,
USA). All amplimers showing abnormal elution profiles
were directly sequenced using the BIG DYE dideoxy-ter-
minator chemistry (Perkin Elmer, USA) on an ABI 377
DNA sequencer (PE Applied Biosystems, USA). Chromas
1.5 software (Technelysium, USA) and LASERGENE
package computer programmes (DNASTAR, USA) were
used to edit, assemble, and translate sequences. A control
group of 250 healthy, unrelated subjects (500 alleles) drawn
from the Italian population was used to rule out the possi-
bility of DNA polymorphisms. For ethical reasons, in
asymptomatic minors, genetic screening was performed
only after detection of the mutation in the family and after
parents’ written consent as recommended by the European
Society of Human Genetics.19
Cardiological screening
Subjects were assessed for the first time because they had a
family history of ARVC (n  24) or of juvenile sudden
death (n  16) due to arrhythmic symptoms (n  9), chest
pain episodes (n  3), and electrocardiogram (ECG) abnor-
malities (n  1). All subjects with clinical signs of the
disease entered a follow-up program with visits every 6
months; otherwise, they had yearly visits.
The study protocol included 12-lead ECG, signal-aver-
aged ECG (SAECG), 24-hour Holter, and two-dimensional
echocardiogram, as described elsewhere.16 Cardiac mag-
etic resonance (CMR) with gadolinium as contrast agent
as performed in selected cases. The following clinical
arameters were considered: age at time of diagnosis and at enrollment for the study, family history of ARVC and/or of
uvenile sudden death, and clinical presentation. Any pal-
itations, syncope, sudden death or aborted sudden death,
nd chest pain were carefully investigated.
The ECG parameters analyzed were incomplete or com-
lete right bundle branch block, negative T waves on pre-
ordial or limb leads, epsilon waves, low QRS voltages, and
T segment elevation in precordial leads. As far as the
resence of negative T waves in V1–V3, we did not con-
ider these ECG features among the diagnostic criteria in
ubjects 12 years old when using 1994 criteria20 and 14
years old when using the modified diagnostic criteria.21
SAECG was performed with the MAC 15 system (Mar-
quette Inc.). Time-domain analysis was done using three
different filters (25, 40, 80 Hz) and was considered positive
when at least two parameters were abnormal with two filter
setting.22 When using 2010 criteria, SAECG was consid-
red positive if late potentials were present in one or more
f three parameters in the absence of a QRS duration of
110 ms.21 The presence of premature ventricular com-
lexes (PVCs) was considered as a criterion, with the
hresholds fixed by the two task forces diagnostic crite-
ia.20,21
The echocardiogram was done with a 2.5- to 4-MHz
transducer (HP 5500) with M-Mode, two-dimensional, and
Doppler examination. LV volumes were calculated using an
ellipsoid biplane area-length model derived from LV im-
ages in the apical four-chamber view. RV volumes were
calculated using an area-length method derived from or-
thogonal planes (apical four-chamber and short-axis sub-
costal views). RV fractional area change was measured
from the apical four-chamber view. Moreover, RV dimen-
sions that have been proposed by the updated 2010 criteria
were also considered.21 Parasternal long axis (PLAX) right
entricular outflow tract (RVOT) was calculated from the
nterior RV wall to the RV septum in the PLAX, and
arasternal short axis (PSAX) RVOT was obtained in
SAX view as the maximum distance between the anterior
ortic wall and the RV free wall. Measures were corrected
or body size area (BSA).
CMR was performed on a 1.0-T clinical scanner (Har-
ony, Siemens, Germany) using a phased-array cardiac
eceiver coil. After the intravenous administration of gado-
inium chelate (0.2 mmol/kg), inversion recovery prepared
reath-hold cine gradient-echo images were obtained23 to
assess late enhancement (LE) according to a previously
described method.24,25 CMR was not performed in asymp-
omatic subjects less than 10 years of age for ethical rea-
ons. In the other cases, CMR was performed in subjects
ith no contraindications and with the parents’ written
onsent.
ARVC was diagnosed according to the 1994 task force
riteria.20 The subjects affected were classified as having
ild, moderate, or severe disease according to the RVnd-diastolic volume (RVEDV) and the presence of RV
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1688 Heart Rhythm, Vol 8, No 11, November 2011wall motion abnormalities.16 The recently proposed modi-
fied criteria were applied,21 classifying subjects as affected,
borderline, or unaffected. Finally, the LE on CMR was
assessed in family members as a potential new diagnostic
criterion.
Statistical analysis
Data are expressed as mean value  standard deviation for
ontinuous variables and as frequencies with percentages
or categorical variables. All continuous variables are ex-
ressed as the mean  standard deviation. An unpaired
tudent’s t-test was used to compare normally distributed
ata. Lifelong event-free survival rates were estimated using
he Kaplan-Meier method, and comparisons were drawn
sing the log-rank test. The following major events were
onsidered: sustained ventricular tachycardia (VT), ventric-
lar fibrillation (VF), cardiac arrest, heart failure, syncope,
Table 1 Mutations in desmosomal genes involved in ARVC
Gene and exon Nucleotide change
PKP2:
Ex1 c.83delC
Ex1 c.184_185delCA
Ex2 c.227A¡G
Ex7 c.1643delG
Ex10 c.2013delC
Ex12 c.2333T¡C
DSP:
Ex1 c.88G¡A
Intr2 c.2735G¡A
Intr3 c.4231G¡A
Ex7 c.897C¡G
Ex11 c.1372A¡T
Ex23 c.3337C¡T
Ex23 c.3774C¡A
Ex23 c.4803G¡A
Ex23 c.4961T¡C
Ex23 c.5324G¡T
Ex24 c.7622G¡A
3’UTR c.*9T¡A
DSG2
Ex4 c.298G¡C
Ex9 c.1174G¡A
Ex12 c.1672C¡T
Ex15 c.2990delG
Multiple mutations:
PKP2 ex1 c.148_151delACAG
DSG2 ex9 c.1174G¡A
PKP2 ex10 c.2119C¡T
DSP ex23 c.4961T¡C
DSP ex9 c.1124A¡T
DSG2 ex13 c.1912G¡A
DSP ex11 c.1408A¡G
DSP ex13 c.1696G¡A
DSP ex23 c.3203_3204delAG
DSG2 ex15 c.2773C¡T
DSP ex23 c.5324G¡T
DSG2 ex6 c.689A¡G
DSG2 ex9 c.1254_1257insATGA
DSG2 ex15 c.2990delG
aMutation c. *495CT in the TGFbeta3 gene was also detected in thisnd chest pain. The P-values were two-sided and consideredtatistically significant when .05. Data were analyzed by
PSS 18 for Windows (SPSS Inc., Chicago).
Results
Among the 53 subjects evaluated under 18 years of age,
26 (49%) had a gene mutation in DSP, 12 (23%) in
PKP2, six (11%) in DSG2, and nine (17%) had multiple
mutations (MM) in one or two different genes (Table 1,
with more detailed information in Supplemental Table
1).4,7,10,13,15,26 – 40 None of the mutations were found in
the control population.
Clinical phenotype at first evaluation
None of the 16 subjects belonging to group A (six males, 10
females, mean age 7.2  2.1 years) fulfilled the 1994
ARVC diagnostic criteria. They were all assessed owing to
a family history of ARVC, except for one who had chest
ino acid change n References
29AfsX10 1
62DfsX23 1 26
76S 2 26
548VfsX15 1a 15, 27–32
672RfsX12 6 15, 26, 28, 30, 31
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2 26
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1689Bauce et al Desmosomal Gene Mutationsin the presence of angiographically normal coronary arter-
ies.
Among the 18 patients belonging to group B (15 males,
three females, mean age 12.6  1 years), 12 (67%) were
studied owing to a family history of ARVC, two for chest
pain, three for ventricular arrhythmias, and one because of
abnormal ECG findings. Six patients (33%, five males, one
female, age range 11–14 years) were diagnosed with
ARVC, and they all had ventricular arrhythmias (sustained
VT in one, nonsustained VT in three, isolated PVCs in two).
Two had a mild form of the disease, two a moderate form,
and two a severe form.
Among the 19 subjects belonging to group C (11 males,
eight females, mean age 16.3  1 years), ARVC diagnosis
as made in eight (42%, six males, two females, age range
5–18 years). The majority of subjects (n  13, 68%) were
tudied owing to a family history of ARVC, and the other
ix (32%) were studied for arrhythmic symptoms. All the
ffected patients had ventricular arrhythmias (sustained VT
n four, nonsustained VT in two, PVCs in two). Two-
imensional echocardiogram demonstrated severe disease
n two, moderate in five, and mild in one.
Thus, a total of 14 subjects (26%, 11 males and three
emales, mean age 15  2 years) were diagnosed with
RVC at first evaluation, whereas the majority (39 [74%],
0 males and 19 females, mean age 11  4 years) showed
o signs or symptoms of the disease.
Clinical phenotype of index cases and family
members
Among 53 subjects, 40 were family members. Among
these, an ARVC diagnosis using modified criteria was ob-
tained in nine cases (22.5%) at the age of 17.8  5.1 years.
Ventricular arrhythmias were present in 27% of family
members versus 100% of index cases (P  .00001), ECG
was abnormal in 15% of family members versus 92% of
index cases (P  .00001), and SAECG was positive in 15%
f family members versus 77% of index cases (P .00001).
Moreover, RV dimensions evaluated with RV PLAX/BSA
and RV PSAX/BSA were found to be significantly lower in
family members compared with index cases.
Twelve-lead ECG
The ECG was found to be abnormal in 12 (23%) patients at
first evaluation, and in 18 (34%) at last follow-up. ECG
findings are given in Table 2.
SAECG
Late potentials were detected in 12 patients (23%) at first
evaluation (none in group A, six in group B, and six in
group C) and in another eight patients during follow-up
(two in group A, five in group B, and one in group C).
Two-dimensional echocardiogram
Twelve subjects (23%) had typical ARVC features at their
first assessment (none in group A, six in group B, and six in
group C), which appeared in another six during the fol- Tab Gro Gro Gro
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1690 Heart Rhythm, Vol 8, No 11, November 2011low-up (two in group A, two in group B, and two in group
C). Disease progression in terms of morphological abnor-
malities was demonstrated during follow-up in 12 cases
(two in group A, three in group B, and seven in group C).
Ventricular arrhythmias
At first evaluation, 17 subjects (32%) showed ventricular
arrhythmias (one in group A, eight in group B, and eight in
group C). In particular, a sustained VT was detected in five
subjects (one in group B and four in group C), and nonsus-
tained ventricular arrhythmias in the other 12 (one in group
A, seven in group B, and four in group C). A detailed
analysis of PVC morphology on 12-lead ECG was available
in nine subjects, showing a left bundle branch block mor-
phology in all (with inferior axis in five and superior axis in
four).
Clinical features in relation to genetic results
At first evaluation, ARVC was diagnosed in three of 26 DSP
mutation carriers (12%; two males and one female, age
15  2 years); in five of twelve PKP2 carriers (42%; four
males and one female, mean age 14  1.6 years); in one of
six DSG2 carriers (17%; male, age 11 years); and in five of
ine MM carriers (56%; four males and one female, mean
ge 16 1.5 years; Table 3). By comparing the clinical and
nstrumental findings in patients carrying different ARVC
ene mutations, no statistically significant differences
mong gene carriers appeared (Table 4). During the follow-
p, DSP mutation carriers had a greater disease progression,
n terms of RV-LV dilatation and dysfunction as well as of
AECG findings, even if they showed smaller RV dimen-
ions at first evaluation (Table 5). At the end of follow-up
mong the 20 subjects who achieved the diagnosis, seven
Table 3 ARVC diagnosis in relation to gene mutation
DSP (n
Index cases 4 (15)
Diagnosis at first evaluationa 3 (12)
Diagnosis at follow-upa 18 years 8 (31)
Diagnosis at last follow-upa 8 (31)
Diagnosis at first evaluation considering proposed
modified criteriab
3 (12)
Diagnosis at follow-up  18 years considering
proposed modified criteriab
8 (31)
Diagnosis at last follow-up considering proposed
modified criteriab
8 (31)
Age at diagnosisa (18 years) 16  2
ge at diagnosisb (18 years) considering
proposed modified criteria
16  2
isease extent at diagnosisa (18 years):
Mild 3
Moderate 3
Severe 2
entricular arrhythmias (18 years) 11 (42)
Note: Numbers in parentheses are percents.
aDiagnosis made using the 1994 task force criteria.20
bDiagnosis made using the 2010 modified criteria.21elonged to the DSP group (27% of all DSP carriers), six tohe PKP2 group (50% of all PKP2 carriers), one to the
SG2 group (17% of all DSG2 carriers), and six to the MM
roup (67% of all MM carriers).
CMR
CMR was performed in 21 (40%) out of 53 subjects and
revealed morphofunctional abnormalities of the RV in nine
(43%) and LV in four (19%). Contrast-enhanced CMR
showed LE in 12 subjects (57%), which was confined to the
RV in two and to the LV in five and was biventricular in five
(see Table 6).
In eight gene mutation carriers (all males, age range
17–30 years, mean 21  6 years), CMR confirmed an
lready established diagnosis of ARVC. Among the remain-
ng 13 who did not fulfill either the 1994 or the 2010
iagnostic criteria (eight males, five females, age range
0–26 years, mean 17  6 years), contrast-enhanced CMR
etected LE in six (46%), that is, five in the LV and one in
he anterior RV free wall. With regard to the eight patients
ot fulfilling the criteria who underwent a CMR examina-
ion before the age of 18, five showed LV LE and one RV
E in the setting of normal RV and LV dimensions and
inetic features (Figure 1).
ARVC diagnosis in the pediatric age
(<18 years)
By applying the 1994 criteria,20 ARVC was diagnosed in 20
out of 53 desmosomal gene mutation carriers (38%, 15
males and five females, age range 11–18 years, mean 15 
2 years), while the other 33 (62%) were considered unaf-
fected. Using the recently modified diagnostic criteria,21 21
cases subjects were labeled as affected (40%, age range
11–18 years, 16 males and five females, mean age at diag-
PKP2 (n  12) DSG2 (n  6) MM (n  9)
4 (33) 1 (17) 4 (44)
5 (42) 1 (17) 5 (56)
5 (42) 1 (17) 6 (67)
6 (50) 1 (17) 6 (67)
5 (42) 1 (17) 5 (56)
5 (42) 1 (17) 7 (70)
6 (50) 1 (17) 7 (78)
17  7 11 16.5  1
17  7 11 17  1
2 0 1
2 0 3
2 1 3
6 (50) 2 (33) 7 (78) 26)nosis 15  2 years), four as borderline (8%), and 28 as
Table 4 SAECG and two-dimensional echo features at first evaluation in 53 desmosomal genes mutation carriers
Gene
mutations No.
Age of
patients
RVOT
(PLAX)/BSA
RVOT
(PSAX)/BSA
RVEDA,
cm2 RVFS
RV kinetic
abn, n (%)
LVEDV,
mL/m2 LVEF, %
LV kinetic
abn, n (%)
Positive
SAECG, n (%)
DSP 26 12  3.94 12.72  2.94 16.39  3.54 15  4 37  8 3 (12) 56  8 63  5 1 (4) 3 (12)
PKP2 12 13  3.7 20.05  4.72 23.11  8.3 21  6 36  7 4 (33) 61  9 62  5 0 3 (40)
DSG2 6 10.8  3.6 18.32  6.46 20.36  6.72 17  6 37  6 1 (17) 58  10 61  3 0 1 (17)
MM 9 13  4.9 21.71  9.44 22.68  9.15 20  7 39  12 5 (56) 56  13 62  8 2 (22) 5 (56)
DSP vs. PKP2 0.460 0.00001 0.001 0.0008 0.712 0.131 0.093 0.570 0.730 0.055
DSP vs. DSG2 0.527 0.0026 0.047 0.305 1 0.744 0.594 0.332 0.622 0.744
PKP2 vs. DSG2 0.247 0.525 0.493 0.201 0.769 0.484 0.529 0.660 1 0.340
DSP vs. MM 0.547 0.0002 0.005 0.012 0.563 0.01 1 0.662 0.106 0.011
DSG2 vs. MM 0.346 0.458 0.604 0.406 0.713 0.155 0.755 0.77 0.239 0.155
PKP2 vs. MM 1 0.62 0.911 0.728 0.479 0.305 0.309 1 0.104 0.476
Table 5 Comparison between SAECG and two-dimensional echo features at first and last evaluation in 53 desmosomal gene mutation carriers
Gene
mutations No.
Age of
patients RVOT (PLAX)/BSA RVOT (PSAX)/BSA RV FS
RVEDA,
cm2
RV kinetic
abn, n (%) LVEDV, mL/m2 LVEF, %
LV kinetic
abn, n (%)
Positive
SAECG,
n (%)
DSP 26 12  3.9 12.72  2.94 16.39  3.54 37  8 15  4 3 (12) 56  8 63  5 1 (4) 3 (12)
DSP 26 19.6  7 16.21  4.48 18.25  3.35 40  9 22  8 8 (31) 65  14 59  7 2 (8) 8 (31)
P .001 .05 .209 .0002 .178 .006 .021 .546 .004
PKP2 12 13  3.7 20.05  4.72 23.11  8.3 36  7 21  6 4 (33) 61  9 62  5 0 (0) 3 (40)
PKP2 12 20.8  8.8 18.05  5.91 19.16  3.25 36  7 23  9 5 (42) 65  11 62  5 2 (17) 4 (33)
P .369 .139 1 .528 .407 .340 1 .149 .184
DSG2 6 10.8  3.6 18.32  6.46 20.36  6.72 37  6 17  6 1 (17) 58  10 61  3 0 1 (17)
DSG2 6 17.8  5 17.15  5.88 16.57  9 40  7 23  10 1 (17) 58  6 61  3 0 1 (17)
P .749 .420 .443 .300 1 1 1 1 1
MM 9 13  4.9 21.71  9.44 22.68  9.15 39  12 20  7 5 (56) 56  13 62  8 2 (22) 5 (56%)
MM 9 26  11.4 17.2  4.28 23.06  4.16 30  6 23  7 6 (67) 61  11 50  7 2 (22) 7 (78%)
P .210 .911 .06 .376 .638 .391 .003 1 .335
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1692 Heart Rhythm, Vol 8, No 11, November 2011unaffected (53%). Contrast-enhanced CMR identified LE in
an additional five cases by the age of 18 years.
Therapy
Antiarrhythmic drug therapy was performed in 17 patients
(beta-blocker in two, sotalol in 10, propaphenon in one,
amiodaron  beta-blocker in two, and dysopiramide 
beta-blocker in two). Moreover, a total of four patients
received an implantable cardioverter-defibrillator (three
males, one female, age range 17–30).
Follow-up
During 9  7 years of follow-up, seven gene mutation
carriers previously considered unaffected were diagnosed as
affected with ARVC (four males and three females, age
range 15–30 years, mean 18  5 years); three of them had
a moderate form and four had a mild form of the disease.
Thus, at the end of follow-up a total of 21 subjects (40%,
mean age 16  4 years) fulfilled the 1994 diagnostic crite-
ia. By applying recently modified criteria, one additional
ubject was diagnosed, for a total of 22 affected cases
41.5%), five borderline (9.5%), and 26 unaffected (49%).
ine subjects (seven males and two females), already con-
idered to be affected at first evaluation, showed disease
rogression in terms of ECG, SAECG, two-dimensional
cho abnormalities, and electrical instability.
With regard to ventricular arrhythmias, during follow-
p, one patient (female, 20 years old) experienced a sus-
Table 6 CMR findings in 21 desmosomal gene mutation
carriers
No. of
patients (%)
Morphofunctional abnormalities 9 (43)
Isolated RV 5
Biventricular 4
LE on contrast enhanced CMR 12 (57)
RV isolated 2
RV inflow 0
RV inferior wall 1
RV outflow 0
RV anterior wall 1
RV apex 0
LV isolated 5
LV anterior wall 3
LV lateral wall 3
LV inferior wall 2
LV septum 2
Biventricular 5
RV inflow 1
RV inferior wall 3
RV outflow 0
RV anterior wall 4
RV apex 0
LV anterior wall 3
LV lateral wall 2
LV inferior wall 4
LV septum 1ained VT and two a VF. Of these, one who had beenassessed at the age of 13 and considered unaffected accord-
ing to both the 1994 and the modified criteria died suddenly
when he was 15 years old as first clinical manifestation of
the disease.10 The other was affected by a moderate form of
he disease with isolated PVCs (1,000/24 hour) and at the
ge of 18 he had a cardiac arrest and was successfully
esuscitated. In addition, two subjects who had previously
xperienced a VT episode had a VT recurrence (at the age
f 17 and 30 years). None of the patients developed heart
ailure. Finally, lifelong event-free survival rates estimated
sing the Kaplan-Meier method did not reveal significant
ifferences in terms of major events between patients car-
ying mutations of different desmosomal genes (P  .352;
Figure 2).
Discussion
ARVC is an inherited heart muscle disease characterized by
progressive myocardial loss with fibrofatty replacement.
Previous studies have shown that, although it is genetically
determined, the disease is not present at birth, and it is
usually diagnosed in young adulthood when the clinical
signs appear, cardiac arrest sometimes being the presenting
manifestation.1,2,16,41 By analyzing a series of subjects car-
rying ARVC-related desmosomal gene mutations who were
evaluated for the first time before the age of 18 years as part
of a family screening program for inherited cardiomyopa-
thies and followed up over a substantial period of time, we
gained some new insights into the ARVC phenotype and
clinical onset.
Age at disease onset
The detection of diagnostic criteria in 38% of subjects
younger than 18 years old suggests that the cardiac pheno-
type appears in young adolescence in a significant number
of subjects carrying ARVC-related gene mutations, while
its clinical onset beyond the age of 18 is less common. In
our series, the age at diagnosis using both the 199420 and the
odified 2010 diagnostic criteria21 was comparable to that
reported in other pediatric populations.17,18
Moreover, CMR provided additional diagnostic informa-
tion, since six of the eight subjects 18 years old who did
not fulfill the diagnostic criteria revealed LE, localized
mainly to the LV, with no other morphological or kinetic
abnormalities detectable by echo. This CMR feature has
already been reported in ARVC patients35,42,43 and supports
he hypothesis that the pathologic hallmark of the disease,
hat is, the myocardial loss followed by fibrofatty replace-
ent, should not be considered exclusive to the RV because
t is often biventricular or confined to the LV.2
Clinical phenotype in young subjects
ARVC can be characterized by a severe phenotype from an
early age, as demonstrated by our pediatric series. As far as
the arrhythmic profile, sustained ventricular arrhythmias
were found at first evaluation in nearly one-third of our gene
mutation carriers, and two subjects suffered a sudden death
all (arr
1693Bauce et al Desmosomal Gene Mutationsand an aborted sudden death. These data confirm the con-
cept that in young patients the risk of life-threatening ven-
tricular arrhythmias is high, probably owing to the peculiar
stage of the pathologic process, characterized by an abrupt
myocardial loss, followed by fibrofatty substitution, to
mimic acute myocardial infarction.10 It is worth adding that
in a transgenic mouse model of DSG2-related ARVC, myo-
cyte necrosis was recently found to be the key initiator of
Figure 1 A: 12-lead ECG of a 10-year-old family member (DSP mutat
The ECG trace is normal. B: SAECG of the same patient, with no late pote
no fat infiltration. D: CMR of the same patient showing LE on the LV wFigure 2 Event-free survival rates in terms of major evenprogressive myocardial dystrophy and that this did not oc-
cur at birth.44
Genotype-phenotype correlations
Subjects carrying DSP mutations had a worse disease progres-
sion in terms of RV and LV dilatation and SAECG features
during follow-up, even though DSP carriers at first evaluation
showed smaller RV dimensions. However, event-free survival
ier) who did not fulfill the 1994 and recently modified diagnostic criteria.
t 40 filter settings. C: CMR of the same patient with T1 sequence showing
ows).ion carr
ntials ats according to the underlying genetic background.
ug
a
t
1694 Heart Rhythm, Vol 8, No 11, November 2011rates did not identify any prognostic role of the genetic back-
ground in terms of major events. Prospective studies on larger
series of genotyped ARVC patients are needed to confirm and
expand these preliminary data.
ARVC diagnostic criteria
According to the new criteria, since a causative mutation is
a major criterion, you need only some additional clinical
features to reach the diagnosis. In fact, the recently modified
criteria21 were more sensitive than the 1994 ones in identi-
fying familial pediatric cases by reducing the prevalence of
unaffected individuals from 62% to 53% under the age of
18. Moreover, contrast-enhanced CMR could detect the
presence of LE, mainly localized to the LV, even in the
absence of wall thinning or kinetic abnormalities in a sub-
stantial proportion of apparently “healthy” carriers. This
supports the concept that genetic data need to be considered
among the ARVC diagnostic criteria, as recommended in
the recently modified 2010 criteria, and that contrast-en-
hanced CMR should enter the diagnostic work-up at an
early stage.
Clinical management of desmosomal gene
mutations carriers
While identifying a desmosomal gene mutation in a person
already diagnosed with ARVC does not substantially influ-
ence the medical approach to the patient, genotyping the
clinically unaffected family members raises the issue of
how to manage these so-called healthy carriers. In our
opinion, competitive sport should be forbidden and CMR
should be repeated yearly because gene mutation carriers
can develop the clinical signs of the disease during adoles-
cence and young adulthood, with life-threatening ventricu-
lar arrhythmias occurring within a relatively short period of
time. Patients should also be advised to report any symp-
toms such as syncope, chest pain, asthenia, or palpitations
promptly. Although the issue of eligibility for competitive
sports remains debatable for gene mutation carriers with no
clinical signs of the disease (and even with negative CMR),
we believe that strenuous effort should be avoided.45
Limitation
To define disease extent, we classified affected subjects as
having a mild, moderate, or severe disease, according to the
RVEDV and the presence of RV wall motion abnormalities,
as we did elsewhere.16 However, we recognize that this
subclassification into mild, moderate, and severe forms is
not widely accepted, particularly when calculated on echo-
cardiographically derived RV volumes. For these reasons,
two-dimensional echo RV dimensions that have been re-
cently proposed by the updated 2010 criteria were also used.
Future aims of the research
The evidence of a different disease penetrance in subjects
carrying the same gene mutations supports the hypothesis
that additional factors, both exogenous and endogenous,
may play a role in modulating the ARVC phenotype. Thesefactors may include athletic activity and male gender, since
competitive athletes seem to be exposed to the risk of an
earlier onset and more rapid progression of the disease
phenotype45 and women appear to be affected less fre-
quently than men, although they may have severe forms of
the disease.46 A better understanding of the additional mod-
lating factors will contribute to the early identification of
ene mutation carriers at higher risk to develop an earlier
nd more severe clinical picture, with the aim to adopt
imely lifestyle and therapeutic preventive strategies.
Appendix
Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.hrthm.
2011.06.026.
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